Semax is a synthetic heptapeptide, a nootropic agent originally developed in Russia, that has been clinically studied for its neuroprotective and cognitive-enhancing properties. It is an analogue of a fragment of adrenocorticotropic hormone (ACTH) and is utilized to improve memory, attention, and executive function. In a clinical context, it is considered a targeted intervention for enhancing neurocognitive performance and resilience.
Origin
Semax was developed by the Russian Academy of Medical Sciences in the 1980s, based on the known neuromodulatory effects of ACTH and its fragments on the central nervous system. Its development represents a targeted approach to creating peptides with high central nervous system activity and low peripheral hormonal side effects.
Mechanism
The primary mechanism involves modulating the activity of several brain neurotrophic factors, most notably increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). By upregulating these factors, Semax promotes neurogenesis, enhances synaptic plasticity, and improves the survival and function of neurons, leading to measurable improvements in cognitive processing and memory recall.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.